Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, small-cap biotech Repligen (RGEN +3.66%) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Repligen and see what CAPS investors are saying about the stock right now.
Repligen facts
|
Headquarters (founded) |
Waltham, Mass. (1981) |
|
Market Cap |
$240.2 million |
|
Industry |
Biotechnology |
|
Trailing-12-Month Revenue |
$65.9 million |
|
Management |
CEO Dr. Walter Herlihy |
|
Trailing-12-Month Return on Equity |
19.6% |
|
Cash/Debt |
$47.9 million / $0 |
|
Competitors |
Bio-Rad Laboratories |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 98% of the 333 members who have rated Repligen believe the stock will outperform the S&P 500 going forward.
Just yesterday, one of those Fools, All-Star zzlangerhans, succinctly summed up the Repligen bull case for our community:
I missed the bump in Repligen's share price in the spring because I set an outperform threshold of 6 that never quite clicked. The stock has been pulling back over the last month but I still like the growing bioprocessing revenues, courtesy of the excellent acquisition of Novozymes Biopharma Sweden AB in 2011. Repligen still has to outgrow a well-deserved reputation for futility but if they can successfully transition from drug development into products and services there's still a lot of potential for share price appreciation.
